BRAF and melanoma: In malignant cells isolated from BRAF mutant melanoma PDXs exposed to RAF/MEK inhibitors, varying combinations of distinct drug-tolerant transcriptional states were identified, which co-existed within MRDs from PDXs and biopsies of patients under therapy.